Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05039216

Biobank for Inflammatory Chronic Diseases and Osteoporosis

Biobank for Inflammatory Chronic Diseases and Osteoporosis of TOULouse

Status
Recruiting
Phase
Study type
Observational
Enrollment
2,000 (estimated)
Sponsor
University Hospital, Toulouse · Academic / Other
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to constitute a biobank for patients followed in the Rheumatology center of Toulouse University Hospital for a chronic inflammatory rheumatism including rheumatoid arthritis (RA), spondyloarthritis(SpA), and psoriatic arthritis (PsA) or a chronic bone disease including osteoporosis in order to identify biomarkers associated with therapeutic response.

Detailed description

Biologic ant targeted synthetic disease modifying anti-rheumatic drugs (bDMARDs and tsDMARDs) have greatly improved the prognosis of chronic inflammatory diseases. To date, many bDMARDs and tsDMARDs targeting different immunologic mechanisms are available to treat RA, SpA or PsA. However, the choice of the treatment and its mechanism of action is based on physician decision and experience. Indeed, predictive clinical and biological factors associated with therapeutic response that could help the physician to make his/her choice are lacking. The aim of BIOTOUL is to collect and store biologic samples in patients with RA, SpA or PsA who begin a new bDMARD or tsDMARD. This biobank will permit to study several biomarkers and assess the association between such markers and response to therapy. Furthermore, osteoporosis is a chronic disease leading to fractures and disability. Several ant-osteoporotic drugs are now available and biomarker(s) that would help the physician to choose the best therapeutic sequence are lacking. BIOTOUL will also include patients with osteoporosis to identify biomarkers associated with severity and response to anti-osteoporotic treatments.

Conditions

Interventions

TypeNameDescription
BIOLOGICALBlood sampling4 tubes of 7 mL will be sampled

Timeline

Start date
2021-09-13
Primary completion
2026-09-02
Completion
2031-09-01
First posted
2021-09-09
Last updated
2026-03-19

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05039216. Inclusion in this directory is not an endorsement.